A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis-Reference-Cited by-同舟云学术

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Published:2024 Issue:8 Volume:15 Page:2622-2642
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Chávez-López Lucia M.¹²,Carballo-López Gabriela I.²,Lugo-Ibarra Karina del Carmen³,Castro-Ceseña Ana B.²⁴^ORCID

Affiliation:

1. Facultad de Medicina, Centro de Estudios Universitarios Xochicalco Campus Ensenada, San Francisco 1139, Fraccionamiento Misión, C.P. 22830, Ensenada, Baja California, Mexico

2. Departamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada, Baja California (CICESE), Carretera Ensenada-Tijuana No. 3918, Zona Playitas, C.P. 22860, Ensenada, Baja California, Mexico

3. Facultad de Ciencias Marinas, Universidad Autónoma de Baja California, C.P. 22860, Ensenada, Baja California, Mexico

4. CONAHCYT – Departamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada, Baja California (CICESE), Carretera Ensenada-Tijuana No. 3918, Zona Playitas, C.P. 22860, Ensenada, Baja California, Mexico

Abstract

The review underscores the need for continuous exploration and innovation, balancing the benefits and challenges of nanotechnology, to combat MASLD and improve patient outcomes comprehensively.

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00420E

Reference145 articles.

1. Non-alcoholic fatty liver disease

2. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss

3. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

4. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease